DelNova, Inc. is a biopharmaceutical company focused on addressing unmet medical needs. DelNova is resolving complications arising from botulinum toxin therapies (eg. Botox®). The first product under development, ReViVox™ is based on a clinically validated drug currently approved for a different medical use and route of administration. The novel formulation will manage undesirable side effects resulting from neurotoxin injections in both medical and cosmetic applications.
Torque3 is developing a neurorehabilitation solution that has shown in early testing to result in significantly better recovery outcomes. A wealth of research over...
In a wide ranging discussion, with Lazurite Co-Founder/CEO Eugene Malinskiy, we learn more about the origins of the company, it's current status, and get...
